452 related articles for article (PubMed ID: 26202561)
1. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
[TBL] [Abstract][Full Text] [Related]
4. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment.
Rubio IT; Esgueva-Colmenarejo A; Espinosa-Bravo M; Salazar JP; Miranda I; Peg V
Ann Surg Oncol; 2016 Jan; 23(1):38-43. PubMed ID: 26514120
[TBL] [Abstract][Full Text] [Related]
6. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy.
Akhsan A; Aryandono T
Asian Pac J Cancer Prev; 2010; 11(3):759-61. PubMed ID: 21039049
[TBL] [Abstract][Full Text] [Related]
8. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
Golshan M; Garber JE; Gelman R; Tung N; Smith BL; Troyan S; Greenberg CC; Winer EP; Ryan P
Ann Surg Oncol; 2011 Mar; 18(3):733-7. PubMed ID: 20882415
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Criscitiello C; Azim HA; Agbor-tarh D; de Azambuja E; Piccart M; Baselga J; Eidtmann H; Di Cosimo S; Bradbury I; Rubio IT
Ann Oncol; 2013 Aug; 24(8):1980-5. PubMed ID: 23567146
[TBL] [Abstract][Full Text] [Related]
10. Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Liu D; Chang L; Hao Q; Ren X; Liu P; Liu X; Wei Y; Wang M; Wu H; Kang H; Lin S
J Cancer Res Clin Oncol; 2024 May; 150(5):285. PubMed ID: 38814494
[TBL] [Abstract][Full Text] [Related]
11. Impact of Breast Reconstruction on Time to Definitive Surgical Treatment, Adjuvant Therapy, and Breast Cancer Outcomes.
Jabo B; Lin AC; Aljehani MA; Ji L; Morgan JW; Selleck MJ; Kim HY; Lum SS
Ann Surg Oncol; 2018 Oct; 25(10):3096-3105. PubMed ID: 30014454
[TBL] [Abstract][Full Text] [Related]
12. 3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy: clinical results and future perspectives with reference to FDG-PET.
Nakamura S; Kenjo H; Nishio T; Kazama T; Do O; Suzuki K
Breast Cancer; 2001; 8(4):351-4. PubMed ID: 11791129
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors associated with involved margins in breast cancer treated with neoadjuvant chemotherapy followed by breast-conserving therapy.
Davoine E; Dion L; Nyangoh Timoh K; Beraud E; Tas P; Tavenard A; Laviolle B; Perrin C; Foucher F; Levêque J; Lavoué V
J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):467-472. PubMed ID: 31207391
[TBL] [Abstract][Full Text] [Related]
14. Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis.
Bowen ME; Mone MC; Buys SS; Sheng X; Nelson EW
Ann Surg; 2017 Mar; 265(3):448-456. PubMed ID: 27280515
[TBL] [Abstract][Full Text] [Related]
15. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
[TBL] [Abstract][Full Text] [Related]
16. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
Man VC; Cheung PS
Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
[TBL] [Abstract][Full Text] [Related]
18. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
[TBL] [Abstract][Full Text] [Related]
19. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
[TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
